BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:27:46 2024-05-16 am EDT			5-day change	1st Jan Change
6.315 ^USD	-0.71%		+17.32%	+4.59%

May. 15	Transcript : BioCryst Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM
May. 15	Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	MT

BioCryst Pharmaceuticals, Inc Announces that Megan Sniecinski, Chief Business Officer of the Company Separate from Employment with the Company

August 09, 2021 at 07:23 am EDT

BioCryst Pharmaceuticals, Inc. (the 'Company') on August 3, 2021, it was determined that Megan Sniecinski, Chief Business Officer of the Company, would separate from employment with the Company. This separation is effective as of August 9, 2021.

Latest news about BioCryst Pharmaceuticals, Inc.

Transcript : BioCryst Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM	May. 15
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	May. 15	MT
BioCryst Pharmaceuticals Shares Rise 20% Following Disclosure of Executive Share Purchases	May. 15	MT
BioCryst Says Orladeyo Granted Approval in Mexico	May. 13	MT
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO	May. 09	CI
JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating	May. 07	MT
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	May. 06	MT
BioCryst Pharmaceuticals Shares Jump After Q1 Beat	May. 06	MT
Transcript : BioCryst Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 06, 2024	May. 06
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024	May. 06	CI
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return	May. 06	DJ
BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil	Apr. 17	MT
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	Apr. 17	CI
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM	Mar. 12
Transcript : BioCryst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases	Feb. 26	MT
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q4 Revenue $93.4M, vs. Street Est of $90M	Feb. 26	MT
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 26	CI
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
North American Morning Briefing : Traders Await Inflation Data This Week	Feb. 26	DJ
BioCryst Launches Hereditary Angioedema Drug in Italy	Feb. 20	MT
BioCryst Launches Orladeyo (Berotralstat) in Italy	Feb. 19	CI
Transcript : BioCryst Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:00 PM	Jan. 09

Chart BioCryst Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - H.C. Wainwright BioConnect Investor Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for BioCryst Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.36 USD

Average target price

14 USD

Spread / Average Target

+120.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOCRYST PHARMACEUTICALS, INC.	+4.59%	1.31B
VERTEX PHARMACEUTICALS INCORPORATED	+7.19%	113B
REGENERON PHARMACEUTICALS, INC.	+11.11%	106B
ARGENX SE	+0.70%	22.27B
BIONTECH SE	-12.21%	22.22B
GENMAB A/S	-5.43%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-5.85%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.88%	14.29B
SAREPTA THERAPEUTICS, INC.	+34.68%	12.52B

Bio Therapeutic Drugs